Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
复制标题
DOI：
10.1016/j.msard.2021.103251
复制
发表时间：
2021-11
影响因子：
4
通讯作者：
Sejbaek T
中科院分区：
文献类型：
--
作者：
Novak F;Nilsson AC;Nielsen C;Holm DK;Østergaard K;Bystrup A;Byg KE;Johansen IS;Mittl K;Rowles W;Mcpolin K;Spencer C;Sagan S;Gerungan C;Wilson MR;Zamvil SS;Bove R;Sabatino JJ;Sejbaek T
接受抗 CD20 单克隆抗体 (Ab) 治疗的患者中 COVID-19 疫苗的免疫原性尚未得到充分研究。 SARS-CoV-2 免疫球蛋白 G (IgG) 的可检测水平被认为对针对 COVID-19 的免疫保护具有预测价值，目前是疫苗功效的替代指标。测定抗 CD20 治疗的多发性硬化症 (MS) 患者的 IgG 抗体。在接种疫苗之前和之后，使用 SARS-CoV-2 IgG II Quant 测定（Abbott Laboratories）测量针对 SARS-CoV-2 刺突受体结合域的 IgG 抗体（n = 60）。 36.7% 的患者在第二剂疫苗后出现 SARS-CoV-2 刺突抗体阳性反应。 5 名患者 (8.3%) 的抗体水平 >264 BAU/mL，另外 12 名患者 (20%) 的抗体水平介于 54 BAU/mL 和 264 BAU/mL 之间，5 名患者 (8.3%) 的抗体水平较低 <54 BAU/mL。在所有血清阳性患者中，63.6% 在接种第 2 次疫苗后从血清阴性转为血清阳性。我们的研究表明，接受 B 细胞耗竭治疗的多发性硬化症患者在接种 BNT162b2 mRNA SARS-CoV-2 疫苗后体液反应下降。临床医生应建议接受抗 CD20 治疗的患者避免接触 SARS-CoV-2。未来的研究应该调查第三种加强疫苗对接种后抗体低或缺失的患者的影响。
The immunogenicity of COVID-19 vaccine among patients receiving anti-CD20 monoclonal antibody (Ab) treatment has not been fully investigated. Detectable levels of SARS-CoV-2 immunoglobulin G (IgG) are believed to have a predictive value for immune protection against COVID-19 and is currently a surrogate indicator for vaccine efficacy. To determine IgG Abs in anti-CD20 treated patients with multiple sclerosis (MS). IgG Abs against SARS-CoV-2 spike receptor–binding domain were measured with the SARS-CoV-2 IgG II Quant assay (Abbott Laboratories) before and after vaccination (n = 60). 36.7% of patients mounted a positive SARS-CoV-2 spike Ab response after the second dose of vaccine. Five patients (8.3%) developed Abs >264 BAU/mL, another 12 patients (20%) developed intermediate Abs between 54 BAU/mL and 264 BAU/mL and five patients (8.3%) had low levels <54 BAU/mL. Of all seropositive patients, 63.6% converted from seronegative to seropositive after the 2nd vaccine. Our study demonstrates decreased humoral response after BNT162b2 mRNA SARS-CoV-2 vaccine in MS patients receiving B-cell depleting therapy. Clinicians should advise patients treated with anti-CD20 to avoid exposure to SARS-CoV-2. Future studies should investigate the implications of a third booster vaccine in patients with low or absent Abs after vaccination.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
影响因子：
9.4
作者：
Addetia A;Crawford KHD;Dingens A;Zhu H;Roychoudhury P;Huang ML;Jerome KR;Bloom JD;Greninger AL
通讯作者：
Greninger AL
影响因子：
5.9
作者：
Achiron A;Mandel M;Dreyer-Alster S;Harari G;Magalashvili D;Sonis P;Dolev M;Menascu S;Flechter S;Falb R;Gurevich M
通讯作者：
Gurevich M
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group